HLB바이오스텝

278650KOSDAQ

62.1 / 100

Reference Date: 2026-09-08

Financial Score21.5 / 40

News Sentiment20.6 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 15.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Biosstep specializes in non-clinical CRO services, particularly in efficacy evaluation for pharmaceutical development, leveraging its expertise in high-complexity experiments using major animals like pigs and beagles. The company expanded its offerings in 2024 by acquiring HLB BioCode, a GLP toxicity testing specialist, and also provides animal facility construction and maintenance services.

Number of Employees

150people

Average Salary

61.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.42Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-18.60Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

6.60Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲18.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼441.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -9.2% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 82.5

Positive
에드믹바이오·HLB바이오스텝, 튜머로이드·MPS 약물평가 개발
HLB바이오스텝과 에드믹바이오의 MOU 체결로 튜머로이드 및 MPS 약물평가 플랫폼 개발이 가속화되어 긍정적인 시장 반응 예상.
Positive
최소 절개로 반려동물 척추 치료…'내시경 수술' 클래스 열린다
HLB바이오스텝 관련 내시경 수술 워크숍 개최로 기술 혁신 및 전문성 강화 기대.
Positive
HLB바이오스텝, 넥셀과 오가노이드·비임상시험 결합한 서비스 구축
HLB바이오스텝이 넥셀과 협력하여 오가노이드 기반 비임상 시험 서비스를 강화함으로써 기술 혁신과 시장 경쟁력을 향상시킬 것으로 기대된다.

Detailed Momentum

52-week position3.0Point

52w lower range (35%)

Current 2,405Won52-week high 4,78552-week low 1,099

1-month return6.0Point

1m +15.62% (strong rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주요사항보고서(자기전환사채만기전취득결정)2026-09-03
Neutral주식등의대량보유상황보고서(일반)2026-08-28
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-27
Neutral반기보고서 (2026.06)2026-08-14